Ann: Immutep Completes Enrolment for TACTI-003 Phase IIb Trial, page-14

Emailed the company yesterday and received a prompt reply this morning...

I hope all is well. Thank you for your email and your support as a shareholder of Immutep.We are pleased to reach this important milestone of completing enrollment in TACTI-003. With respect to the Quarterly Activities Report published on the 27th April, it noted that Immutep expected TACTI-003 "to complete enrolment by mid-year positioning the Company to report top-line results in H2 of CY2023". With the enrollment completing in November, the Company expects to report data from the trial in H1 CY2024 as detailed in yesterday's press release. This timeline also was disclosed in the latest quarterly report at the end of October. Also for your reference, the Baird Discovery Series webcast earlier today provided an overview and insights into TACTI-002, TACTI-003, and AIPAC-003, among other items. If you did not get a chance to listen in, here is the webcast link that can also be found under our Events page. Please let me know if you have any additional questions.